Not Yet RecruitingNot Applicable

Multicenter Registration Study on Allergic Bronchopulmonary Aspergillosis

China300 participantsStarted 2024-10-15

Plain-language summary

To understand the current diagnosis and treatment status of ABPA patients, observe their clinical characteristics, prognosis, and treatment outcomes, and identify the relevant factors for poor prognosis in patients.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Meeting the diagnosis of ABPA according to the ABPA diagnostic criteria specified by the ISHAM-ABPA working group in 2024 Exclusion Criteria: ABPA patients who are not first diagnosed in the center

What they're measuring

Clinical classification and treatment response criteria for ABPA

Timeframe: 1 year

Trial details

NCT IDNCT06645210

SponsorPeking University Third Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Allergic Bronchopulmonary Aspergillosis trials